AU2002320828B2 - Treatment or prophylaxis of insulin-producing cell graft rejection - Google Patents

Treatment or prophylaxis of insulin-producing cell graft rejection Download PDF

Info

Publication number
AU2002320828B2
AU2002320828B2 AU2002320828A AU2002320828A AU2002320828B2 AU 2002320828 B2 AU2002320828 B2 AU 2002320828B2 AU 2002320828 A AU2002320828 A AU 2002320828A AU 2002320828 A AU2002320828 A AU 2002320828A AU 2002320828 B2 AU2002320828 B2 AU 2002320828B2
Authority
AU
Australia
Prior art keywords
insulin
macrocyclic lactone
antibody
acceptable salt
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002320828A
Other languages
English (en)
Other versions
AU2002320828A1 (en
Inventor
Philip Lake
Claudy Mullon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2002320828A1 publication Critical patent/AU2002320828A1/en
Application granted granted Critical
Publication of AU2002320828B2 publication Critical patent/AU2002320828B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
AU2002320828A 2001-06-08 2002-06-07 Treatment or prophylaxis of insulin-producing cell graft rejection Ceased AU2002320828B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29706901P 2001-06-08 2001-06-08
US60/297,069 2001-06-08
PCT/EP2002/006278 WO2002100148A2 (en) 2001-06-08 2002-06-07 Treatment or prophylaxis of insulin-producing cell graft rejection

Publications (2)

Publication Number Publication Date
AU2002320828A1 AU2002320828A1 (en) 2003-05-15
AU2002320828B2 true AU2002320828B2 (en) 2006-02-02

Family

ID=23144725

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002320828A Ceased AU2002320828B2 (en) 2001-06-08 2002-06-07 Treatment or prophylaxis of insulin-producing cell graft rejection

Country Status (18)

Country Link
US (5) US20030003099A1 (enExample)
EP (1) EP1429845B1 (enExample)
JP (1) JP4476623B2 (enExample)
CN (1) CN1524002A (enExample)
AT (1) ATE424893T1 (enExample)
AU (1) AU2002320828B2 (enExample)
BR (1) BR0209319A (enExample)
CA (1) CA2445605A1 (enExample)
DE (1) DE60231522D1 (enExample)
ES (1) ES2322442T3 (enExample)
IL (1) IL158384A0 (enExample)
NO (1) NO20035434D0 (enExample)
NZ (1) NZ529044A (enExample)
PL (1) PL364359A1 (enExample)
PT (1) PT1429845E (enExample)
RU (1) RU2003136730A (enExample)
WO (1) WO2002100148A2 (enExample)
ZA (1) ZA200307893B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60213766T2 (de) * 2001-02-22 2007-08-02 Novartis Ag Verwendung von beschleunigten lymphozyten zielansteuernden wirkstoffen zur herstellung eines medikaments für die behandlung der verzögertern transplantat-funktion
JP5161567B2 (ja) * 2004-05-14 2013-03-13 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体活性を阻害することによる同種移植片の生存の延長
PL1772145T3 (pl) * 2004-07-16 2011-08-31 Kyorin Seiyaku Kk Sposób skutecznego stosowania leku i sposób dotyczący zapobiegania efektom ubocznym
CN102600472A (zh) * 2004-11-29 2012-07-25 诺瓦提斯公司 S1p受体激动剂的剂量方案
US20080206240A1 (en) * 2005-02-08 2008-08-28 Shreeram Aradhye Antilymphocyte Antibody Induction
AU2006247857B2 (en) * 2005-05-11 2009-10-22 Loma Linda University Substances, compositions and methods for preventing and treating immune-mediated inflammatory disorders
US20090191218A1 (en) 2005-05-11 2009-07-30 Fengchun Li DNA Vaccines And Methods For The Prevention Of Transplantation Rejection
CN101346346B (zh) * 2005-12-15 2012-08-22 田边三菱制药株式会社 胺化合物及其医药用途
WO2007103134A2 (en) * 2006-03-02 2007-09-13 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
CA2663026C (en) * 2006-09-28 2013-04-16 Loma Linda University Apoptotic cell-mediated transfection of mammalian cells with interfering rna
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
ES2965333T3 (es) * 2008-03-12 2024-04-12 Univ Loma Linda Vacunas de ADN y procedimientos de prevención de rechazo tras un trasplante
HRP20170246T4 (hr) 2008-03-17 2020-02-07 Actelion Pharmaceuticals Ltd. Režim doziranja za selektivni agonist s1p1-receptora
BRPI0921533A2 (pt) * 2008-11-11 2016-01-12 Novartis Ag composto orgânicos
MX2011004962A (es) * 2008-11-11 2011-05-30 Novartis Ag Formas cristalinas de hcl de fingolimod.
BRPI1016004A2 (pt) * 2009-06-30 2016-04-26 Lifescan Inc métodos para testar analitos e dispositivo para calcular a terapia de insulina basal.
EP2449493A2 (en) * 2009-06-30 2012-05-09 Lifescan Scotland Limited Systems for diabetes management and methods
BR112012007134A2 (pt) * 2009-09-29 2016-08-23 Lifescan Scotland Ltd dispositivo e método de teste de analito para controle de diabetes
WO2011106029A1 (en) * 2010-02-25 2011-09-01 Lifescan Scotland Limited Analyte testing method and system with high and low blood glucose trends notification
DK2758074T3 (da) 2011-09-23 2020-07-27 Univ Loma Linda Bakteriestammer der udtrykker methylasegener og anvendelser deraf
US11680273B2 (en) 2011-09-23 2023-06-20 Loma Linda University Treatment of autoimmune diseases
CN114306643A (zh) * 2021-11-30 2022-04-12 中国科学院昆明动物研究所 一种恒河猴免疫抑制模型的构建方法及在car-t细胞植活上的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952316A (en) * 1992-10-21 1999-09-14 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
US6004565A (en) * 1997-09-02 1999-12-21 Yoshitomi Pharmaceutical Industries, Ltd. Compositions and methods of using compositions with accelerated lymphocyte homing immunosuppressive properties

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679546A (en) * 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
EP0750458B1 (en) * 1994-03-03 2003-08-27 Alexion Pharmaceuticals, Inc. Terminal complement inhibitor fusion genes and proteins
GB9624038D0 (en) * 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
DE60213766T2 (de) * 2001-02-22 2007-08-02 Novartis Ag Verwendung von beschleunigten lymphozyten zielansteuernden wirkstoffen zur herstellung eines medikaments für die behandlung der verzögertern transplantat-funktion

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952316A (en) * 1992-10-21 1999-09-14 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
US6004565A (en) * 1997-09-02 1999-12-21 Yoshitomi Pharmaceutical Industries, Ltd. Compositions and methods of using compositions with accelerated lymphocyte homing immunosuppressive properties

Also Published As

Publication number Publication date
ZA200307893B (en) 2004-09-06
JP2004534788A (ja) 2004-11-18
US20080199465A1 (en) 2008-08-21
CA2445605A1 (en) 2002-12-19
PL364359A1 (en) 2004-12-13
CN1524002A (zh) 2004-08-25
US20030003099A1 (en) 2003-01-02
BR0209319A (pt) 2004-07-20
JP4476623B2 (ja) 2010-06-09
WO2002100148A3 (en) 2004-04-22
RU2003136730A (ru) 2005-05-20
DE60231522D1 (de) 2009-04-23
US20060153842A1 (en) 2006-07-13
EP1429845A2 (en) 2004-06-23
US20110236382A1 (en) 2011-09-29
NZ529044A (en) 2008-03-28
NO20035434D0 (no) 2003-12-05
ATE424893T1 (de) 2009-03-15
ES2322442T3 (es) 2009-06-22
PT1429845E (pt) 2009-06-15
IL158384A0 (en) 2004-05-12
WO2002100148A2 (en) 2002-12-19
EP1429845B1 (en) 2009-03-11
US20140093502A1 (en) 2014-04-03

Similar Documents

Publication Publication Date Title
AU2002320828B2 (en) Treatment or prophylaxis of insulin-producing cell graft rejection
AU2002320828A1 (en) Treatment or prophylaxis of insulin-producing cell graft rejection
US20080015261A1 (en) Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function
KR100634847B1 (ko) 췌장도 조직 이식을 위한 ｃｄ154 차단 요법
AU2004226807B2 (en) Parenteral formulation of mycophenolic acid, a salt or prodrug thereof
AU2010305385B2 (en) Inhibitors of CXCR1/2 as adjuvants in the transplant of pancreatic islets
CN120283040A (zh) 用于1型糖尿病治疗的具有免疫调节剂、dyrk1a抑制剂和glp1r激动剂的组合疗法
US20010041179A1 (en) CD25 binding molecules for use in the treatment of manifestations of rejection in transplantation
TZE et al. HUMAN ISLET XENOGRAFT SURVIVAL IN DIABETIC RATS A FUNCTIONAL AND IMMUNOHISTOCHEMICAL STUDY
JPS62190123A (ja) 免疫抑制剤
EP0430983B1 (en) Use of castanospermine as an anti-inflammatory and immunosuppressant agent
HK1060855B (en) Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function
JP5727167B2 (ja) Ｎｃｘを標的とした単離膵島ならびに移植膵島障害の新規制御法
AU2008200659A1 (en) Parenteral formulation of mycophenolic acid, a salt or prodrug thereof
WO2006005620A1 (en) Use of manzamines in transplantation and autoimmune diseases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired